Kura Oncology, Inc. earnings per share and revenue
On Nov 04, 2025, KURA reported earnings of -0.85 USD per share (EPS) for Q3 25, beating the estimate of -0.86 USD, resulting in a 2.16% surprise. Revenue reached 20.75 million, compared to an expected 42.08 million, with a -50.69% difference. The market reacted with a +1.94% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.68 USD, with revenue projected to reach 56.27 million USD, implying an decrease of -20.00% EPS, and increase of 171.19% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
FAQ
What were Kura Oncology, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Kura Oncology, Inc. reported EPS of -$0.85, beating estimates by 2.16%, and revenue of $20.75M, -50.69% below expectations.
How did the market react to Kura Oncology, Inc.'s Q3 2025 earnings?
The stock price moved up 1.94%, changed from $9.77 before the earnings release to $9.96 the day after.
When is Kura Oncology, Inc. expected to report next?
The next earning report is scheduled for Feb 24, 2026.
What are the forecasts for Kura Oncology, Inc.'s next earnings report?
Based on 16
analysts, Kura Oncology, Inc. is expected to report EPS of -$0.68 and revenue of $56.27M for Q4 2025.